Researchers at the University of Washington have announced plans to ask the FDA to move a fentanyl vaccine into human trials, reports Oregon Public Broadcasting (OPB). A vaccine would be an additional way to combat opioid use disorder because researchers believe it will reduce the risk of overdose and relapse. Reports OPB:

Lab director Marco Pravetoni began working on opioid vaccines more than a decade ago, when oxycodone was the main addiction culprit.

“At the time there were about 30,000 people dying each year of opioid overdose,” he says. “Those numbers seemed huge already. They were comparable to some cancer.”

Pravetoni goes on to say that after COVID-19 the situation grew even worse. Government data shows there were more than 100,000 annual overdose deaths in the years following the pandemic, a trend led by synthetic opioid fentanyl. The Pacific Northwest has been hit especially hard by opioids. Oregon and Washington ranked eighth and third, respectively, out of 50 U.S. states for overdose deaths between 2021 and 2023.

Opioid molecules are so very, very small they can breach the brain barrier without interference from the immune system. In fact, the immune system doesn’t see the molecules because they are so small. There is literally no alarm bell that goes off when opioids enter the body. This is why they work so quickly and effectively for pain relief. The rapid entry is also why they are so easily abused and potentially deadly.

Vaccines work by training the body’s immune system to recognize the shape of an invader. Vaccines need molecules big enough to be recognized, or the molecules will be ignored. Here again is the problem. The opioid molecules are too small for both the immune system to recognize and for the development of a vaccine. Or so it seemed.

Researchers found a creative way to make the vaccine. They engaged in a little bit of biological deception. First, scientists made a copycat molecule, called a hapten, that is opioid-like in structure but not in behavior. Then, they attach these haptens all over the surface of a comparatively massive protein they know the immune system will be able to see.

OPB again:

“That’s like putting a small smiley face sticker on a stop sign. The stop sign would be the protein. It’s something that’s large enough for the immune system to recognize it and say, ‘Oh, I need to make an antibody,’” [Courtney Marecki, University of Washington chemist] says.

Then, when actual fentanyl shows up down the road, the antibodies spring into action. They bind to the fentanyl molecules, making them too large to pass through the barrier protecting the brain.

“The antibodies are not just preventing the drug from getting to the brain, [they] seem also to have effects on craving. We see that in animal models and even in our preliminary clinical data with the oxycodone vaccine,” says [Lab director Marco] Pravetoni.

Developed further, this could prevent people from overdosing and also help reduce dependency on opioids, too, by reducing their pleasurable effects. Early research suggests the effects could last a year.

Like the medications that are used to reduce alcohol use, and the apparent side effects of others (like GLP-1), vaccines offer another tool to address addiction. The COVID-19 vaccine advanced our understanding of the immune response. Now researchers are continuing to investigate what might be possible. For example, last year AddictionNews reported on similar work underway to develop a vaccine to address cocaine addiction.

Opioid use disorder in particular seems to coexist with those experiencing long-term social and economic hopelessness. Opioid fatalities tracked with the rise of “deaths of despair” that rose during and after the COVID-19 pandemic. The effects can be generational: Children of parents who suffered deaths of despair have nearly double the risk of suicide or self-harm.

A vaccine for opioids would be a tremendous win for individuals and their families. Yet, we still need to address the chronic, debilitating stress. The need for relief drives all addictions. 

Written by Katie McCaskey. First published September 21, 2026.

Sources:

“Northwest researchers develop vaccines to prevent opioid overdose and support addiction recovery,” Oregon Public Broadcasting, September 10, 2026.

“The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy,” National Library of Medicine, May 9, 2008.

“Opioid Overdose Deaths: National Trends and Variation by Demographics and States,” KFF, February 24, 2026. 

Deaths of Despair and the Future of Capitalism, Anne Case and Angus Deaton, Princeton University Press, March 17, 2020.

“Deaths of Despair: What Are They and Why do They Matter?,” Psychology Today, October 15, 2025.

Image Copyright: fabrikacrimea.